Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of ABBV-637 alone or with docetaxel or osimertinib in relapsed/refractory solid tumors
jRCT2031210468Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ABBV-637 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants experiencing adverse events and Objective response rate. Started Apr 2021; status: active, not recruiting.
02
Drugs
ABBV-637
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210468.